Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Frozen vs. claw: which biopsy tool wins for lung diagnosis?

NCT ID NCT05751278

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from Johns Hopkins University compared two methods for taking lung tissue samples during a bronchoscopy: a 1.1mm cryoprobe (which freezes tissue) versus standard 2.0mm forceps (which grab tissue). The trial enrolled 500 adults scheduled for a lung biopsy and measured how often each tool led to a clear diagnosis, as well as bleeding complications. The goal was to see if the newer cryoprobe technique is more effective and safe than the traditional forceps approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the cryoprobe proves better, it could become the new standard tool for lung biopsies, improving diagnosis for lung diseases.
What could go wrong
This is a completed device comparison study, so results are already known. The cryoprobe may not show a meaningful advantage over forceps, and any new tool carries risks like bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

500 people

The number who actually took part.

Started

Feb 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female, ≥ 18-years-old * Scheduled to undergo bronchoscopy with transbronchial biopsy per standard of care Exclusion Criteria: * Pregnant or nursing woman or woman of child-bearing potential who refuse to take a pregnancy test prior to enrollment * Severe pulmonary hypertension (RVSP \> 60 mmHg) * Stroke within the last 6 months or myocardial infarction within the last 3 months * Presence of bleeding disorder * Platelet count \< 50,000 per mL at time of enrollment * Use of systemic anticoagulation or antiplatelet therapy without the ability to hold therapy for the recommended time prior to invasive procedure (aspirin monotherapy is acceptable) * Do Not Resuscitate (DNR) status * Do Not Intubate (DNI) status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung diseases

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Northwestern Medicine

    Chicago, Illinois, 60611, United States

  • The Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • University of Maryland, Baltimore (UMB)

    Baltimore, Maryland, 21201, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee, 37232, United States

  • Washington University in Saint Louis (Wash-U)

    St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.